Summer 2020 Vol. 10 Issue 02
-
From the Editor-in-Chief
Measuring a Cancer Drug’s Effectiveness
Surrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Your Cancer Guide
Not Our First Rodeo
During the COVID-19 pandemic, cancer survivors can tap into familiar lessons of resiliency.
by Hester Hill Schnipper
-
Caregiving With Confidence
The Power of Anger
Accepting this emotion can be the first step in channeling it for a constructive purpose.
by Karen J. Bannan
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical Trials
The AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
A Delicate Balance
Cancer patients with chronic pain and the physicians who treat them strive to address pain while avoiding potential opioid abuse and addiction.
by Charlotte Huff
-
Keeping CLL in Check
With recent advances in targeted treatments, people diagnosed with chronic lymphocytic leukemia have more options to manage the disease.
by Kendall K. Morgan
-
Robotic Surgery and Cancer
Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.
by Sue Rochman
-
Survivor Profile
Sharing Her Strength
Diagnosed with two cancers prior to turning 40, Rebecca Esparza uses her voice to advocate for policy changes to help people affected by cancer.
by Lindsey Konkel
-
Q&A
Taking the Long View
In her first book, journalist and breast cancer survivor Kate Pickert traces the winding road of cancer research and patient advocacy.
by Marci A. Landsmann
-
Sound Advice
Your Questions, Our Answers
Weight gain during treatment, conversations about sex, and what to know about a loved one's insurance.
-
Facts and Stats
A Quarter Century of Progress Against Lung Cancer
While advances have been made in treating lung cancer and risk reduction, there is still plenty of work to be done.
by Bradley Jones
Cancer Talk
Evidence grows that some people with HER2-positive breast cancer may do well on HER2-targeted therapy alone.
by Myles Starr
Germline Genetic Testing Lags Behind GuidelinesLow rates of germline genetic testing in cancer patients means information that could affect treatment isn’t available.
by Jon Kelvey
Progress in Lung CancerNovember is Lung Cancer Awareness Month. Here are stories describing lung cancer treatment advances and the experiences of people who have been through a diagnosis.
Against All OddsAt age 26, Manny Garcia was diagnosed with and fought pancreatic cancer.
by Karon Warren